# CD19/22 Bi-specific CAR-T Cell Therapy

> **NCT05432882** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 60 (estimated)

## Conditions studied

- B Cell Malignancies

## Interventions

- **BIOLOGICAL:** bi-4SCAR CD19/22 T cells

## Key facts

- **NCT ID:** NCT05432882
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-30
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05432882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05432882, "CD19/22 Bi-specific CAR-T Cell Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05432882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*